Skip to main content

Table 1 Demographics, CV medication experience and HAART effectiveness in three different time periods

From: Consistent use of lipid lowering therapy in HIV infection is associated with low mortality

Baseline characteristics over time (Median (IQR) or %) 1996–2000 2001–2005 2006–2011 Overall
n = 7434 n = 7855 n = 7987 n = 23,276
Age 50 (44–56) 53 (47–60) 56 (48–64) 53 (46–60)
Female 1.9% 2.4% 3.3% 2.5%
Race
 African American 38% 48% 53% 46%
 White 34% 39% 37% 37%
 Unknown 27% 12% 8% 15%
Smoking 52% 59% 57% 56%
HCV co-infection 34% 27% 19% 26%
CD4 (/mm3) 312 (170–486) 312 (176–484) 355 (220–512) 328 (189–496)
VL LOG before HAART 4.2 (3.3–4.9) 4.6 (3.5–5.2) 4.5 (3.5–5.0) 4.4 (3.4–5.0)
Years HIV Diagnosis-VL suppression 2.9 (0.9–5.3) 3.4 (0.9–7.4) 2.9 (0.8–7.9) 3.0 (0.9–6.6)
Prior CV Medication Exposure
 LLT 2% 9% 12% 8%
 AHT 17% 25% 30% 24%
 ASA 4% 6% 6% 5%
HAART at study inclusion
 None 7% 12% 4% 8%
 Unboosted PI, no TDF 76% 19% 3% 32%
 Unboosted PI with TDF 0% 3% 2% 2%
 Boosted PI, no TDF 5% 17% 13% 12%
 Boosted PI with TDF 0% 11% 25% 12%
 EFV or INSTI, no TDF 12% 29% 12% 18%
 EFV or INSTI with TDF 0% 9% 41% 17%
One-year HAART adherence (Median) 65% 74% 84% 79%
One-year virologic suppression (Mean) 75% 70% 83% 78%
\